Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.66 |
| ▸ | HTR3B | O95264 | 1/20 | 0.66 |
| ▸ | HTR5A | P47898 | 1/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7281541 | 1.00 | HTR3A (0.66) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL3500096 | 1.00 | HTR3A (0.66) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| Hydrochloric Acid SCHEMBL10342447 | 0.99 | MAPK1 (0.66) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| Hydrochloric Acid SCHEMBL10342444 | 0.99 | MAPK1 (0.66) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2229649 | 0.87 | HTR3A (0.73) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2229644 | 0.87 | HTR3A (0.73) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2228215 | 0.85 | CHRNA7 (0.64) | HTR3ACHRNA7 | |
| SCHEMBL7281094 | 0.85 | CHRNA7 (0.64) | HTR3ACHRNA7 | |
| SCHEMBL2228214 | 0.85 | CHRNA7 (0.64) | HTR3ACHRNA7 | |
| SCHEMBL2230467 | 0.85 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | claimed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | claimed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | claimed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | claimed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | claimed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | claimed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | claimed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | claimed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | claimed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | claimed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | claimed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | claimed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA4 | HTR3A 571/4885HTR3E 633/4885HTR3B 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.